1. <cite id="jzxlt"><span id="jzxlt"></span></cite><cite id="jzxlt"></cite>
            <ruby id="jzxlt"></ruby>

            <ruby id="jzxlt"></ruby>

                <rt id="jzxlt"></rt>
                <rt id="jzxlt"><optgroup id="jzxlt"></optgroup></rt>


                roductsand services

                Innovative Drugs

                Home > Products & services > Innovative Drugs

                SPN003 / SPN004

                Candidate drug screening is going to be completed.

                SPN003/SPN004 are  innovative peptide drugs with synergistic effect on target,  with metabolic diseases including type 2 diabetes and obesity as the main indications.


                Candidate drug screening  has been completed, preclinical studies  are under way.

                SPN007 is a new polypeptide drug with proprietary intellectual property rights. Its indications have expanded from simply lowering blood glucose levels in type 2 diabetes to treating obesity and non-alcoholic fatty liver disease (NASH).


                At the stage of preclinical studies.

                Spn009 is an innovative long-acting hypoglycemic drug  for type 2 diabetes mellitus.


                At the stage of candidate drug screening.

                SPN-X is a peptide inhibitor against the novel coronavirus main protease.

                Mobile version


                Sales Department: